Antibacterial drug discovery and development--SRI's 11th Annual Summit.
Hawser
Stephen P
SP
Arpida Ltd, Dammestrasse 36, CH-4142 Munchenstein, Switzerland. shawser@arpida.ch
D000617:Aminoglycosides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002511:Cephalosporins / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D015994:Incidence; D000077427:Lipoglycopeptides; D016106:Methicillin Resistance; D008911:Minocycline / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D015394:Molecular Structure; D023303:Oxazolidinones / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D013844:Thiazoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000078304:Tigecycline
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000077427:Lipoglycopeptides; D023303:Oxazolidinones; D013844:Thiazoles; D000078304:Tigecycline; D008911:Minocycline; C487637:telavancin